Humana (HUM)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-29
$417.56+1.38%
Close 2026-10-29 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-29
Research Workspace
Put HUM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain EPS guidance of at least $9.00 for FY 2026: Diluted EPS: $5.73 per share.
View ThesisRevenue growth is accelerating — up about 18% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 44% in its worst 12-month stretch.
View RiskHumana’s Medicare Advantage Star Ratings and revenue engine are central to its recovery case. Revenue growth accelerated from 8% to 26% year over year; Q2 FY2026 EPS beat consensus. HUM trades at 24× P/E versus a 23× peer median. That modest gap contrasts with expectations that look modest versus our view. The specific risk is FY2026 diluted EPS of $5.73 against guidance of at least $9.00. Fragile earnings quality means reported profits are not well backed by cash. Peer multiples imply a price about 4% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. HUM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering HUM (as of Oct 2026).
Based on 17 Wall Street analysts offering 12-month price targets for HUM in the last 4 months.
Continue this research
Compare HUM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HUM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put HUM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $417.56
The last 12 months of price, then the range of analyst 12-month targets from today’s $417.56.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Large-scale plan exits threaten MA membership growth and reflect pressure managing the Star Ratings environment.
Advances: Expand CenterWell and Medicaid platforms
Partnership enhances CenterWell expansion efforts.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Star Ratings impact on Medicare Advantage business is concerning.
Advances: Manage impact of Star Ratings on Medicare Advantage business
Improved Star Ratings positively impact Medicare Advantage business.
Advances: Manage impact of Star Ratings on Medicare Advantage business
Upgrade reflects confidence in Star Ratings and business outlook.
Advances: Manage impact of Star Ratings on Medicare Advantage business
Positive movement in stock linked to improved Star Ratings.
Advances: Manage impact of Star Ratings on Medicare Advantage business
Star ratings upgrade positively impacts Medicare Advantage business.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Cuts to Part B Giveback may impact Medicare Advantage membership.
